^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    onvatilimab (CI-8993)

    i
    Other names: CI-8993, JNJ-61610588, JNJ 61610588
    Associations

    News

    Trials
    Company:
    Curis, ImmuNext
    Drug class:
    VISTA antagonist
    Related drugs:
    Associations

    News

    Trials
    4ms
    Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993. (PubMed, Eur J Nucl Med Mol Imaging)
    We radiolabelled and validated [89Zr]Zr-Df-CI-8993 for specific binding to huVISTA in vivo. Our results demonstrate that 89Zr-labelled CI-8993 is now suitable for targeting and imaging VISTA expression in human trials.
    Journal
    |
    VSIR (V-Set Immunoregulatory Receptor)
    |
    onvatilimab (CI-8993)
    1year
    CI-8993-101: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=26, Completed, Curis, Inc. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    onvatilimab (CI-8993)